appConfigEntityId

bodyType

customContents

entityId

entityUuid

isVideo

articlePageQuery

article

articleSchemaContent

content

hooksArticlePageAdvertisementConfigArticle

hooksArticlePageFloatingButtonConfigArticle

appConfig

filter

json

liveArticle

Shi Huang

Imagine swapping your daily cholesterol pill for a single injection that keeps “bad” cholesterol under control for a year, a decade – or even a lifetime.
Two clinical trials, one in the United States and another in China, suggest that this one-and-done approach could become a reality.
Low-density lipoprotein cholesterol (LDL-C), better known as “bad” cholesterol, is a major driver of heart disease – the leading cause of death worldwide. Triglycerides, another type of blood fat, add to the risk.


For millions of people, the standard fix is a daily statin pill.
Research led by the Cleveland Clinic in the US and carried out in Australia, New Zealand and Britain, tested a gene-editing nanodrug called CTX310 on 15 volunteers.
The therapy uses tiny particles to carry a CRISPR gene-editing tool straight into liver cells. Its target is a gene named ANGPTL3, which helps control how much fat circulates in the blood.
Some people are born with a natural mutation that inhibits ANGPTL3. They have extremely low cholesterol and triglycerides, and they rarely develop heart disease.
CTX310 is designed to mimic that genetic switch.
The results, published in The New England Journal of Medicine on August 28, were dramatic. One year after a single intravenous injection, the four volunteers who received the highest dose saw their ANGPTL3 levels fall an average 78.6 per cent, according to the paper.
Their bad cholesterol dropped by 52.5 per cent and triglycerides fell by 47.8 per cent. Even more encouraging, the edited liver cells kept producing new, healthy cells with the same cholesterol-lowering edit – suggesting that the effect might be permanent.
It follows the publication of a paper by Chinese scientists at Shanghai Jiao Tong University’s Renji Hospital in Nature Medicine in March, which focused on patients with an inherited form of dangerously high cholesterol called familial hypercholesterolaemia (FH).
People with FH are born with faulty cholesterol-clearance machinery and face a heart attack risk 10 to 20 times higher than normal, often requiring lifelong medication.
The Chinese team used a different gene-editing tool called an adenine base editor to target the PCSK9 gene which – when overactive – destroys the liver’s ability to remove bad cholesterol from the blood. By “switching off” PCSK9, the nanodrug lets the liver clean house again.
Like the US trial, the numbers were encouraging. In the high-dose group, LDL-C fell by an average of 52.3 per cent after 24 weeks – nearly double the effect of typical statins. The team reported that the PCSK9 protein levels had dropped 74.4 per cent without creeping back up.
The teams behind both trials said their research showed the treatments to be safe. In the Chinese study, participants were reported to experience mild, temporary side effects such as fever, muscle aches or slight liver enzyme changes.
In the US study, one patient died suddenly 179 days after receiving the lowest dose. Investigators concluded the death was unrelated to the drug, according to the paper.
No other serious events were reported.
Gene editing, which has aided patients battling cancer, is now being rolled out to help fight chronic diseases because many genes that helped our ancestors survive famines or malaria have become health hazards in the modern world.
During a famine, genes that could raise blood sugar and lipid levels were advantageous but in the modern era, these genes can lead to severe metabolic problems.
Similarly, while a single thalassaemia gene continues to protect against severe malaria, inheriting severe thalassaemia leads to life-threatening anaemia.


A single nanodrug jab could rewrite those genetic instructions.
Clinical trials on hyperlipidaemia in both the US and China are still under long-term continuous observation.
“The therapy is being assessed in separate cohorts of patients with specific lipid disorders,” Cleveland Clinic cardiologist and corresponding author Steven Nissen said at the end of the American paper.
The Chinese team, when interviewed in March by the Liberation Daily outlet in Shanghai, said it would conduct long-term follow-up research up to 15 years for patients in its clinical trials to monitor treatment effects, and would also seek to improve the lipid nanoparticle formulation.


China’s self-powered neural device helps stroke survivors walk naturally

China’s FAST telescope maps neutral hydrogen, the cosmic gas for making stars

Chinese scientists develop new oil refining method that may cut energy use by 90%

Science

US, China trials suggest a single nanodrug shot might stop bad cholesterol forever

Two breakthrough clinical trials suggest that patients with high cholesterol may one day benefit from a one-and-done injection to keep bad cholesterol under control. Photo: Shutterstock Images

Chinese doctors get double-thigh amputee to walk again in world first

The double-thigh replantation is a global first, according to the Jiangsu Trauma and Treatment Association – a local hospital network. Photo: Shutterstock

The patient, surnamed Jiang, is now able to walk indoors with a frame and manages most of his personal tasks on his own. Photo: QQ.com/Suzhou Ruihua Orthopaedic Hospital

Just three months after the first surgeries, Jiang was able to raise his legs freely while lying down. Photo: QQ.com/Suzhou Ruihua Orthopaedic Hospital

Will Trump’s proposed drug tariffs end India’s reign as ‘pharmacy of the world’?

Employees work inside a pharmaceutical company manufacturing unit on the outskirts of Ahmedabad, India, in April 2025. Photo: Reuters

President Donald Trump has said the US will impose 100 per cent tariffs on generic medicines from August 2028 and increase them to 200 per cent after one year. Photo: AP

A medical ampoule production line at a pharmaceutical factory. Observers say Indian pharmaceutical companies would need to actively diversify their markets in light of Trump’s move. Photo: Shutterstock

A production line for mass-produced blue capsules. Bain and Company data shows India holds the highest number of FDA-registered and compliant manufacturing plants outside the US. Photo: Shutterstock

Asian healthcare deals heat up as investors bet big on brain tech and surgical robotics

An orthopedic surgical robot is displayed at the 2026 World Robot Conference in Beijing on August 20. Photo: Xinhua

China rushes to develop Moderna-style cancer vaccines amid market frenzy

Chinese biotechnology firms are working on more than 100 cancer vaccine programmes, according to analysts. Photo: Shutterstock

As drug giants grow cautious, can Chinese biotech firms still cash in on licensing deals?

Asset id: 2156561481

Cross-border out-licensing deals are proving profitable for Chinese drugmakers. Photo: Shutterstock Images

Cross-border out-licensing deals are proving profitable for Chinese drugmakers. Photo: Shutterstock

News

China

Separate trials using CRISPR and base editing to silence lipid genes show drastic drops in LDL-C without daily medication


Separate trials using CRISPR and base editing to silence lipid genes show drastic drops in LDL-C without daily medication.


US, China trials suggest a single nanodrug shot might stop bad cholesterol forever

.css-1c6uqr6{color:inherit;font-weight:inherit;font-size:inherit;font-family:inherit;line-height:inherit;overflow-wrap:break-word;}Separate trials using CRISPR and base editing to silence lipid genes show drastic drops in LDL-C without daily medication

Separate trials using CRISPR and base editing to silence lipid genes show drastic drops in LDL-C without daily medication